These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 24947465)

  • 1. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization.
    Oosterhof CA; El Mansari M; Blier P
    J Pharmacol Exp Ther; 2014 Dec; 351(3):585-95. PubMed ID: 25225185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity.
    Paluchowska MH; Mokrosz MJ; Charakchieva-Minol S; Duszyńska B; Kozioł A; Wesołowska A; Stachowicz K; Chojnacka-Wójcik E
    Pol J Pharmacol; 2003; 55(4):543-52. PubMed ID: 14581712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
    Ishima T; Futamura T; Ohgi Y; Yoshimi N; Kikuchi T; Hashimoto K
    Eur Neuropsychopharmacol; 2015 Apr; 25(4):505-11. PubMed ID: 25687838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
    Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
    McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
    Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of presynaptic 5-HT
    Mombereau C; Arnt J; Mørk A
    Pharmacol Biochem Behav; 2017 Feb; 153():141-146. PubMed ID: 28057524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.
    Jantschak F; Brosda J; Franke RT; Fink H; Möller D; Hübner H; Gmeiner P; Pertz HH
    J Pharmacol Exp Ther; 2013 Oct; 347(1):57-68. PubMed ID: 23863695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole has a low risk of dopamine D
    Amada N; Akazawa H; Ohgi Y; Maeda K; Sugino H; Kurahashi N; Kikuchi T; Futamura T
    Neuropsychopharmacol Rep; 2019 Dec; 39(4):279-288. PubMed ID: 31487433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator.
    Yoshimi N; Futamura T; Hashimoto K
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):356-64. PubMed ID: 25600995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
    Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2011 Oct; 668(3):355-65. PubMed ID: 21816144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
    Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
    J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A positron emission tomography occupancy study of brexpiprazole at dopamine D
    Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
    Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.